Filtered By:
Specialty: Drugs & Pharmacology
Nutrition: Vitamins

This page shows you your search results in order of date. This is page number 18.

Order by Relevance | Date

Total 271 results found since Jan 2013.

Consideration of clinical variables for choosing new anticoagulant alternatives to warfarin for the management of non‐valvular atrial fibrillation
Summary What is known and objectivePatients with non‐valvular atrial fibrillation (NVAF) are at risk for stroke and systemic embolism (SSE), and this risk can be decreased with adjusted‐dose warfarin. Warfarin, however, is cumbersome to use and requires at least monthly laboratory monitoring. Three new oral anticoagulants (NOACs) that are less cumbersome have been approved as alternatives to warfarin for SSE prevention in NVAF. Selecting a patient‐specific alternative to warfarin can be confusing for pharmacists and clinicians. This review details clinical parameters to consider when choosing an alternative to warfar...
Source: Journal of Clinical Pharmacy and Therapeutics - September 25, 2014 Category: Drugs & Pharmacology Authors: Y. Lu, R. Branstad, R. M. Karim, R. W. Asinger Tags: Review Article Source Type: research

Vitamin K Antagonist Treatment in Patients With Atrial Fibrillation and Time in Therapeutic Range in Four European Countries.
The objective of this study was to evaluate time in the therapeutic range and its relationship to clinical outcomes in patients with nonvalvular atrial fibrillation prescribed a vitamin K antagonist in everyday clinical practice in 4 European countries (France, Germany, Italy and the United Kingdom). METHODS: Data were extracted from the European electronic primary care database, the Longitudinal Patient Database. Included in the analysis were 6250 adult patients for whom data on monitoring of coagulation time and international normalized ratio were available. The time within the therapeutic range was estimated by usi...
Source: Clinical Therapeutics - August 20, 2014 Category: Drugs & Pharmacology Authors: Cotté FE, Benhaddi H, Duprat-Lomon I, Doble A, Marchant N, Letierce A, Huguet M Tags: Clin Ther Source Type: research

Appropriateness of Prescribing Dabigatran Etexilate and Rivaroxaban in Patients With Nonvalvular Atrial Fibrillation: A Prospective Study.
CONCLUSIONS:: Inappropriate use of DE and rivaroxaban in patients with NVAF is frequent and possibly leads to AEs. Reinforcing education of health care professionals and patients is needed. Collaboration with clinical pharmacists can contribute to better use. PMID: 24982310 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - June 30, 2014 Category: Drugs & Pharmacology Authors: Larock AS, Mullier F, Sennesael AL, Douxfils J, Devalet B, Chatelain C, Dogné JM, Spinewine A Tags: Ann Pharmacother Source Type: research

Atrial Fibrillation and Chronic Kidney Disease in Hypertension: A Common and Dangerous Triad.
Abstract Hypertension (HTN) and chronic kidney disease (CKD) often coexist sharing common pathophysiological factors that both in combination and separately induce fibrotic changes in the heart provoking atrial fibrillation (AF). AF, per se, is associated with a 4- to 5-fold increased risk of stroke and a 2-fold increased risk of all-cause death. The co-existence of AF with HTN and renal dysfunction considerably increases morbidity and mortality. Management of AF in hypertensive patients with CKD is complex and multidisciplinary, since these patients have both a prothrombotic state and a coagulopathy with an incre...
Source: Current Vascular Pharmacology - May 19, 2014 Category: Drugs & Pharmacology Authors: Tsiachris D, Tsioufis C, Mazzone P, Katsiki N, Stefanadis C Tags: Curr Vasc Pharmacol Source Type: research

Cost-Effectiveness of Apixaban Versus Other New Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation.
CONCLUSIONS: Although our analysis was limited by the absence of head-to-head trials, based on the indirect comparison data available, our model projects that apixaban may be a cost-effective alternative to dabigatran 150 mg BID, dabigatran 110 mg BID, and rivaroxaban 20 mg once daily for stroke prevention in AF patients from the perspective of the United Kingdom National Health Services. PMID: 24508420 [PubMed - as supplied by publisher]
Source: Clinical Therapeutics - February 5, 2014 Category: Drugs & Pharmacology Authors: Lip GY, Kongnakorn T, Phatak H, Kuznik A, Lanitis T, Liu LZ, Iloeje U, Hernandez L, Dorian P Tags: Clin Ther Source Type: research

Non‐vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions
This article reviews current knowledge and important unanswered questions on the use of these agents in patients with cardiovascular disease. MethodsA literature search was performed using PubMed and the search terms dabigatran, rivaroxaban, apixaban, AF and acute coronary syndrome (ACS). Peer‐reviewed, published clinical trials, review articles, relevant treatment guidelines and prescribing information documents were identified and reviewed for relevance. Results and discussionDabigatran is an oral direct thrombin inhibitor; rivaroxaban and apixaban are oral direct Factor Xa inhibitors. These agents have a quicker onset...
Source: Journal of Clinical Pharmacy and Therapeutics - January 3, 2014 Category: Drugs & Pharmacology Authors: J. W. Cheng, G. Barillari Tags: Review Article Source Type: research

Antivitamin k drugs in stroke prevention.
Abstract Among the different subtypes of ischaemic strokes, almost 20 % are of cardiac origin. Different are the causes of cardioembolic stroke, but the most common is the atrial fibrillation, a supraventricular arrhythmia. Appropriate use of antiplatelet drugs and anticoagulants after transient ischaemic attack (TIA) or ischaemic stroke depends on whether the underlying cause is cardioembolic or of presumed arterial origin. Adequate antiplatelet therapy is recommended for secondary prevention after cerebral ischaemia of presumed arterial origin, whether for patients with TIA and ischaemic stroke of cardiac origin...
Source: Current Vascular Pharmacology - January 1, 2014 Category: Drugs & Pharmacology Authors: Di Raimondo D, Tuttolomondo A, Butta C, Lucifora B, Licata G, Pinto A Tags: Curr Vasc Pharmacol Source Type: research

Metabolic Syndrome and Non-Cardiac Vascular Diseases: an Update from Human Studies.
Abstract The metabolic syndrome (MetS) is characterized by a cluster of risk factors including central obesity, hypertension, dyslipidemia and insulin resistance, The MetS is associated with an increased risk for cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM). Several international organizations have defined MetS using different diagnostic criteria that produced discrepancies in the results of previous studies, thus leading to the latest Joint Interim Societies (JIS) MetS definition. Other risk factors than the diagnostic criteria that have been associated with MetS include lipid abnormalities, u...
Source: Current Pharmaceutical Design - December 5, 2013 Category: Drugs & Pharmacology Authors: Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP Tags: Curr Pharm Des Source Type: research

Novel Oral Anticoagulants and Atrial Fibrillation: Efficacy and Safety Considerations
Abstract For almost six decades, vitamin K antagonists (e.g., warfarin) were the only available oral drugs for the prevention of thromboembolism in patients with atrial fibrillation. Recently, novel oral anticoagulants that target thrombin (dabigatran) or activated factor X (rivaroxaban and apixaban) have successfully completed clinical development and received approval for stroke prevention in atrial fibrillation. Novel oral anticoagulants have been shown to be noninferior, or in some cases superior to warfarin in both safety and efficacy aspects. Their advanced pharmacological properties result to rapid, consisten...
Source: Drug Development Research - November 15, 2013 Category: Drugs & Pharmacology Authors: Stavros Apostolakis Tags: Clinical Commentary Source Type: research

Novel anticoagulants for stroke prevention in atrial fibrillation: safety issues in the elderly.
Abstract Vitamin K antagonists (VKAs) are the most widely used anticoagulants for stroke prevention in patients with atrial fibrillation (AF). Recently, the US FDA approved three novel anticoagulants that work through inhibition of coagulation cascade independent of Vitamin K-dependent enzymatic reactions and, therefore, should have less food-drug interactions. Since AF is a disease of the aging heart, it is important to assess safety and efficacy of these new anticoagulants in elderly patients. We reviewed age-related changes in pharmacokinetics and pharmacodynamics observed with senescence and the effects of the...
Source: Pharmacological Reviews - November 1, 2013 Category: Drugs & Pharmacology Authors: Strunets A, Mirza M, Sra J, Jahangir A Tags: Expert Rev Clin Pharmacol Source Type: research

Novel Therapeutics for Thromboprophylaxis in Nonvalvular Atrial Fibrillation
Abstract Atrial fibrillation (AF) is both a health and a social problem. AF is related to the elevated risk of thromboembolic events with stroke being the most important. It adversely affects life expectancy and quality. The risk of ischemic stroke is increased fivefold in patients with AF. Therapeutic options for lowering the risk of stroke in patients with AF consist of vitamin K antagonists and antiplatelet agents, which have relative risk reductions of approximately 60% and 20%, respectively. Alternative therapeutic options available to reduce the risk of stroke in patients with nonvalvular AF are relatively new...
Source: Drug Development Research - October 21, 2013 Category: Drugs & Pharmacology Authors: Emine Gazi, Ahmet Temiz, Ahmet Barutcu, Yucel Colkesen Tags: Clinical Research Overview Source Type: research

Treatment of Dabigatran-Associated Bleeding: Case Report and Review of the Literature
We report a case involving an 84-year-old male with acute kidney injury who developed life-threatening gastrointestinal and surgical site bleeding secondary to dabigatran accumulation. Use of the Naranjo probability scale indicated a probable cause between the bleeding event and dabigatran use. After discontinuation of drug therapy, fresh frozen plasma, recombinant coagulation factor VIIa, and cryoprecipitate were administered as potential reversal agents with negligible benefit. However, this patient appeared to slowly benefit with administration of continuous venovenous hemodialysis. Based upon our experience with this p...
Source: Journal of Pharmacy Practice - June 5, 2013 Category: Drugs & Pharmacology Authors: Harinstein, L. M., Morgan, J. W., Russo, N. Tags: Adverse Drug Events Source Type: research

Current State of Knowledge on Oral Anticoagulant Reversal Using Procoagulant Factors(June).
CONCLUSIONS:Patients contemplating using the new oral anticoagulants should be informed about specific clinical situations that could pose a bleeding risk such as the need for emergency surgery because no reliable antidote is available to stop the bleeding, which could prove fatal. PMID: 23695644 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - May 21, 2013 Category: Drugs & Pharmacology Authors: Nitzki-George D, Wozniak I, Caprini JA Tags: Ann Pharmacother Source Type: research

Oxidative Stress and Pathophysiology of Ischemic Stroke: Novel Therapeutic Opportunities.
Abstract Stroke is the second leading cause of death, after ischemic heart disease, and accounts for 9% of deaths worldwide. According to the World Health Organization [WHO], 15 million people suffer stroke worldwide each year. Of these, more than 6 million die and another 5 million are permanently disabled. Reactive oxygen species [ROS] have been implicated in brain injury after ischemic stroke. There is evidence that a rapid increase in the production of ROS immediately after acute ischemic stroke rapidly overwhelm antioxidant defences, causing further tissue damage. These ROS can damage cellular macromolecules ...
Source: CNS and Neurological Disorders Drug Targets - February 27, 2013 Category: Drugs & Pharmacology Authors: Rodrigo R, Fernández-Gajardo R, Gutiérrez R, Matamala JM, Carrasco R, Miranda-Merchak A, Feuerhake W Tags: CNS Neurol Disord Drug Targets Source Type: research

Rivaroxaban: an oral factor xa inhibitor.
CONCLUSIONS: Based on the findings of the studies reported in this review, rivaroxaban is an effective option for the prevention of VTE after orthopedic surgery, stroke prevention for nonvalvular AF, and treatment of VTE. At this time, rivaroxaban cannot be recommended for secondary risk reduction after ACS because of the increased bleeding risk. PMID: 23328267 [PubMed - in process]
Source: Clinical Therapeutics - January 1, 2013 Category: Drugs & Pharmacology Authors: Thomas TF, Ganetsky V, Spinler SA Tags: Clin Ther Source Type: research